Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Amgen, Inc.    AMGN   US0311621009

AMGEN, INC.

 (AMGN)

51
SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisionsForum 

Amgen, Inc. : Amgen Sets Pricing on Euro and Sterling Bond

09/10/2012| 04:20am US/Eastern
Recommend:
0

By Sarka Halas

U.S.-based biotechnology company Amgen Inc. (AMGN) has set pricing on its two-part, euro and sterling denominated bond, one of the banks running the deal said Monday.

Pricing on the 17-year euro bond was set in the range of 80 to 85 basis points over midswaps, while pricing on the seven-year sterling part was set in the area of 190 basis points over gilts.

Barclays PLC, Citigroup Inc., and Deutsche Bank AG are the lead managers on the deal, which is expected to price later Monday.

The issuer is rated Baa1 by Moody's Investor Services, A+ by Standard and Poor's Corp., and BBB by Fitch Ratings.

Write to Sarka Halas at sarka.halasova@dowjones.com

Recommend :
0
Partner Area
React to this article
 
Latest news on AMGEN, INC.
1h ago AMGEN, INC.: Amgen Announces Voting Results of Annual Meeting of Stockholders
6d ago AMGEN, INC.: Amgen To Present At The UBS Global Life Sciences Conference
7d ago AMGEN, INC.: Amgen Highlights Data To Be Presented At American Society of Clini..
05/14 AMGEN, INC.: ex-dividend day
05/10DJMedicare Overpaid $529 Million for Anemia Drugs in 2011 - Report
05/09DJAMGEN, INC.: Amgen Forms China Joint Venture
05/09DJAMGEN, INC.: Amgen Forms China Joint Venture With Zhejiang Beta Pharma
05/09 AMGEN, INC.: Amgen And Zhejiang Beta Pharma Announce Planned Joint Venture In C..
05/07DJAMGEN, INC.: Amgen Trial of Colon Cancer Drug Meets Goal
05/07DJAMGEN, INC.: Amgen Late-Stage Trial of Colon Cancer Drug Meets Goal
Advertisement
Chart
Duration : Period :
Amgen, Inc. Technical Analysis Chart | AMGN | US0311621009 | 4-Traders
Income Statement Evolution
Amgen, Inc. : Income Statement Evolution
More Financials
Dynamic quotes  
ON
| OFF
Copyright © 2013 Surperformance. All rights reserved.